Référentiel des médicaments
Ponesimod
Ponesimod is a medicine in the class central nervous system. It is used for multiple sclerosis.
- Classe médicamenteuse: Central Nervous System
- Indications: multiple sclerosis
Dernière mise à jour
Réservé aux professionnels de santé — à titre de référence uniquement. Cette page est un bref résumé, pas un avis médical, et ne remplace ni la notice officielle ni le jugement clinique. Vérifiez toujours avant de prescrire ou de délivrer.
Le contenu clinique de cette page n'est disponible qu'en anglais.
L'essentiel
- Classe médicamenteuse
- Central Nervous System
- Code ATC
- L04AE04
- Formes courantes
- comprimé
- Dosages courants
- 20 mg, 2 mg, 10 mg
- Interactions connues
- 127 (Contre-indiquée: 2 · Majeure: 46 · Modérée: 71 · Mineure: 8)
- Noms commerciaux
- 5
- Pays et marchés
- 4
Indications
Mécanisme d'action
Sphingosine 1-phosphate (S1P) receptor 1 modulator that binds with high affinity to S1P receptor 1
Posologie adulte habituelle (résumé de la notice)
Multiple Sclerosis (Initiation) Starter pack must be used for initiating treatment: 2 mg PO qDay initially; increase dose as per dose titration regimen (14-day titration)
Grossesse et allaitement
- Grossesse
- Unsafe EU label: contraindicated in pregnancy. In rats and rabbits it caused fetal death and malformations at clinical exposures without maternal toxicity (S1P receptor role in embryo development); another S1P modulator raised birth-defect risk in humans. Use contraception; stop 1 week before conceiving.
- Allaitement
- Unsafe No human milk data; rat offspring were exposed via milk. US label: weigh benefits; EU label: risk cannot be excluded, should not be used while breastfeeding. LactMed: long half-life and possible infant toxicity; experts advise avoiding the related fingolimod.
Effets indésirables signalés
- Somnolence
- Elevated hepatic transaminases
- Hypertension
- Urinary tract infection
- Dyspnea
- Dizziness
Contre-indications
- Presence of Mobitz type II second-degree, third-degree AV block, or sick sinus syndrome, unless patient has functioning pacemaker
- In the past 6 months, experienced myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure (HF) requiring hospitalization, or Class III/IV HF
Précautions particulières
- Consider possibility of severe exacerbation of disease after discontinuing therapy; monitor for severe increase in disability upon discontinuation and appropriately treat; after stopping therapy in the setting of PML, monitor for development of immune reconstitution inflammatory syndrome (PML-IRIS)
- Elevated transaminases may occur; if symptoms (eg, unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, rash with eosinophilia, jaundice, dark urine) occur during therapy, check hepatic enzymes; if significant liver injury confirmed, discontinue therapy
Informez votre pharmacien ou votre médecin en cas de grossesse ou d'allaitement, de maladie rénale ou hépatique, d'allergies, ainsi que de tout autre médicament ou complément que vous prenez.
Principales interactions (127)
- Fingolimod + Ponesimod Contraindicated
- Ponesimod + Siponimod Contraindicated
- Amiodarone + Ponesimod Major
- Amisulpride + Ponesimod Major
- Anagrelide + Ponesimod Major
- Anti-thymocyte + Ponesimod Major
- Asenapine + Ponesimod Major
- Atenolol + Ponesimod Major
- Atenolol-chlorthalidone + Ponesimod Major
- Betaxolol + Ponesimod Major
Réservé aux membres Pro+
Débloquer la page complète
Créez un compte et lancez un essai Pro+ pour ouvrir la monographie complète de Ponesimod : posologie, grossesse et allaitement, effets indésirables, mises en garde et toutes les interactions.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Paediatric dosing
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
Essayez Pro+ gratuitement pendant 14 jours sur le web. Sans carte.
Autres médicaments de cette classe
Questions fréquentes
What is Ponesimod used for?
Ponesimod is a medicine in the class central nervous system. It is used for Multiple sclerosis.
What side effects have been reported with Ponesimod?
Somnolence, Elevated hepatic transaminases, Hypertension, Urinary tract infection, Dyspnea, Dizziness.
Can Ponesimod be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. EU label: contraindicated in pregnancy. In rats and rabbits it caused fetal death and malformations at clinical exposures without maternal toxicity (S1P receptor role in embryo development); another S1P modulator raised birth-defect risk in humans. Use contraception; stop 1 week before conceiving. Breastfeeding: Unsafe. No human milk data; rat offspring were exposed via milk. US label: weigh benefits; EU label: risk cannot be excluded, should not be used while breastfeeding. LactMed: long half-life and possible infant toxicity; experts advise avoiding the related fingolimod.
What does Ponesimod interact with?
MediHelp lists 127 known interactions for Ponesimod. Contraindicated: 2 · Major: 46 · Moderate: 71 · Minor: 8. The most serious include Fingolimod, Siponimod, Amiodarone.
Monographies complètes, posologies et vérificateur d'interactions dans l'application MediHelp
Ouvrez le référentiel complet, vérifiez les interactions entre plusieurs médicaments et utilisez les outils de posologie dans l'application MediHelp.
